Just – Evotec Biologics develops and operates an end-to-end continuous manufacturing platform designed to lower the cost of antibody therapies and biosimilars. The company was founded in 2014 and employs over 400 scientists and engineers across its sites in Seattle and Redmond, Washington, and in Toulouse, France.
Its central product, the J.POD facility, is an award-winning continuous manufacturing plant. These facilities are smaller and faster to build than traditional plants, utilizing intensified continuous processes, single-use systems, and AI-driven optimization. The design enables commercial-scale biologics production at a cost target of $50 per gram or lower, a fraction of the traditional price.
The company's work spans the technical domains of biopharmaceutical manufacturing, continuous bioprocessing, and AI-driven optimization. It partners with other biotechnology and pharmaceutical companies, operating with a stated mission to expand global access to biotherapeutics.
